3 days ago
9
Soumya Eswaran
Wed, February 18, 2026 astatine 7:30 AM CST 3 min read
Jacob Funds, a communal money company, released its fourth-quarter 2025 capitalist letter. A transcript of the aforesaid tin beryllium downloaded here. After an optimistic quarter, equity markets corrected somewhat successful November. Although wide economical maturation has been robust passim the year, caller divergent information connected user spending and the labour marketplace person enactment uncertainty connected aboriginal projections. This signifier has go somewhat acquainted implicit the past fewer years, arsenic conflicting economical information has go the norm. As for the Fund’s strategy, the caller moderation successful AI tech companies seems beneficial, and the steadfast believes the caller productivity rhythm volition accelerate nett margins and net growth, resulting successful weaker labour markets. Small companies could payment from this trend, resulting successful imaginable enlargement successful valuation multiples, and successful turn, beryllium favorable for its Funds compared to peers. In addition, delight cheque the Funds’ apical 5 holdings to cognize its champion picks successful 2025.
In its fourth-quarter 2025 capitalist letter, Jacob Funds highlighted stocks similar Prime Medicine, Inc. (NASDAQ:PRME). Prime Medicine, Inc. (NASDAQ:PRME) is simply a biotechnology institution that specializes successful cistron editing technology. On February 17, 2026, Prime Medicine, Inc. (NASDAQ:PRME) banal closed astatine $3.31 per share. One-month instrumentality of Prime Medicine, Inc. (NASDAQ:PRME) was -17.46%, and its shares are up 0.76% implicit the past 12 months. Prime Medicine, Inc. (NASDAQ:PRME) has a marketplace capitalization of $597.49 million.
Jacob Funds stated the pursuing regarding Prime Medicine, Inc. (NASDAQ:PRME) successful its 4th fourth 2025 capitalist letter:
"The Jacob Discovery Fund added 2 caller positions successful the quarter, Cabaletta Bio and Prime Medicine, Inc. (NASDAQ:PRME). Prime Medicine is simply a next-generation cistron therapy institution we person followed for a while, and judge the clip is close to marque an concern fixed our expanding assurance we person successful their exertion and the tremendous upside imaginable should it beryllium viable. While the tract of cistron therapy has suffered its stock of setbacks and concerns implicit the past respective years – safety, durability and outgo each stay obstacles to broader adoption – we are inactive convinced that galore patients suffering from galore chronic and deadly diseases volition beryllium efficaciously cured by cistron therapies. Prime’s elegant and precise cistron editing function, if successfully developed, volition let for simpler and safer attraction options, with little off-target enactment created by the messier double-stranded DNA breaks associated with first-generation cistron therapy technologies similar CRISPR. We are inactive successful precise aboriginal days of premier editing’s development, but a information merchandise precocious past twelvemonth successful the company’s archetypal objective proceedings showed promising efficacy and information signals successful 2 patients."
English (CA) · 
English (US) · 
Spanish (MX) ·